Omalizumab: NICE to USE you, to LOSE you NICE

Thorax. 2013 Jan;68(1):7-8. doi: 10.1136/thoraxjnl-2012-202969.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Administration, Inhalation
  • Adolescent
  • Adult
  • Age Factors
  • Anti-Asthmatic Agents / administration & dosage*
  • Anti-Asthmatic Agents / adverse effects
  • Antibodies, Anti-Idiotypic / administration & dosage*
  • Antibodies, Anti-Idiotypic / adverse effects
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Asthma / drug therapy*
  • Asthma / immunology
  • Child
  • Female
  • Guideline Adherence
  • Humans
  • Male
  • Omalizumab
  • Practice Guidelines as Topic*
  • Risk Assessment
  • Severity of Illness Index
  • Treatment Outcome
  • United Kingdom
  • Young Adult

Substances

  • Anti-Asthmatic Agents
  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal, Humanized
  • Omalizumab